Dyslipidemia of central obesity and insulin resistance

Diabetes Care

Volumn 22, Issue SUPPL. 3, 1999, Pages

  Brunzell, John D ^a   Hokanson, John E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FATTY ACID; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

BODY FAT; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC OBESITY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HORMONE ACTION; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; OBESITY; SYNDROME;

EID: 0032913707     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (69)

1. Albrink MJ, Meigs JW: The relationship between serum triglycerides and skinfold thickness in obese subjects. Ann NY Acad Sci 131:673-683, 1965
2. Davidson P, Albrink MJ: Abnormal plasma insulin response with high plasma triglycerides independent of clinical diabetes or obesity. J Clin Invest 45:1000, 1966
3. Bagdade JD, Bierman EL, Pone D Jr: The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and non-diabetic subjects J Clin Invest 46:1549-1557, 1967
4. Reaven GM, Lerner RL, Stern MP, Farquhar JW: Role of insulin in endogenous hypertriglyceridaemia. J Clin Invest 46:1756-1767, 1967
5. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
6. Avogaro P, Crepaldi G: Essential hyperlipidemia, obesity and diabetes. Diobetotogia 1:137, 1965
7. Haffner SM: The insulin resistance syndrome revisited. Diabetes Care 19:275-277, 1996
8. Austin MA, King M-C, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82:495-506, 1990
9. Vague J: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and unc calculous disease. Am J Clin Nutr 4:20-34, 1956
10. Kissebah AH, Vydelingum N, Murray RW, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW: Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54:254-260, 1982
11. Krotkiewski M, Björntorp P, Sjöström L, Smith U: Impact of obesity on metabolism in men and women: importance of regional adipose tissue distribution. J Clin Invest 72:1150-1162, 1983
12. Ashwell M, Cole TJ, Dixon AK: Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography. BMJ 290:1692-1694, 1985
13. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui SC: Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54-59, 1987
14. Shuman WP, Newell-Morris LL, Leonetti DL, Wahl PW, Moceri VM, Moss AA, Fujimoto WY: Abnormal body fat distribution detected by computed tomography in diabetic men. Invest Radial 21:483-487, 1986
15. Sparrow D, Borkan GA, Gerzof SG, Wisniewski C, Silbert CK: Relationship of fat distribution to glucose tolerance: results of computed tomography in male participants of the normative aging study. Diabetes 35:411-415, 1986
16. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD: The visceral adiposity syndrome in Japanese-American men. Obes Res 2:364-371, 1994
17. Desprès J-P, Moorjani S, Ferland M, Tremblay A, Lupien PJ, Nadeau A, Pinault S, Theriault G, Bouchard C: Adipose tissue distribution and plasma lipoprotein levels in obese women, importance of intraabdominal fat. Arteriosclerosis 9:203-210, 1989
18. Olefsky J, Farquhar JW, Reaven G: Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes 22:507-513, 1973
19. Olefsky JM, Reaven GM, Farquhar JW: Effects of weight reduction on obesity: studies of carbohydrate and lipid metabolism. J Clin Invest 53:64-76, 1974
20. Nevin DN, Schwartz RS, Kahn SE, Brunzell JD: Metabolic associations in insulin resistance syndrome: effect of weight perturbation. Circulation 88:1455, 1993
21. DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177-269, 1997
22. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer J, Porte D Jr: The contribution of insulin dependent and insulin independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes 43:587-592, 1994
23. Terry RB, Wood PDS, Haskell WL, Stefanick ML, Krauss RM: Regional adiposity patterns in relation to lipids, lipoprotein cholesterol, and lipoprotein subtraction mass in men. J Clin Endocrinol Metab 68:191-199, 1989
24. Katzel LI, Bleecker ER, Rogus EM, Goldberg AP: Sequential effects of aerobic exercise training and weight loss on risk factors for coronary disease in healthy, obese middle-aged and older men. Metabolism 46:1441-1447, 1997
25. Schwartz RS, Cain KC, Shuman WP, Larson V, Stratton JR, Beard JC, Kahn SE, Cerqueira MD, Abrass IB: Effect of intensive endurance training on lipoprotein profiles in young and older men. Metabolism 41:649-654, 1992
26. Soler-Argilaga C, Russell RL, Werner HV, Heimberg M: A possible role of calcium in the action of glucagon, cAMP and dibutyryl cAMP on the metabolism of free fatty acids by rat hepatocytes. Biochem Biophys Res Commun 85:249-256, 1978
27. Sparks JD, Sparks CE: Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1215:9-32, 1994
28. Yang LY, Kuksis A, Myher JJ, Steiner G: Contribution of de novo fatty acid synthesis to very low density lipoprotein triacylglycerols: evidence from mass isotopomer distribution analysis of fatty acids synthesized from [2H6]ethanol. J Lipid Res 37:262-274, 1996
29. Grundy SM. Mok HYI, Zech L, Steinberg D, Berman M: Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin invest 63:1274-1283, 1979
30. Pykalisto OJ, Smith PH, Brunzell JD: Determinants of human adipose tissue LPL. J Clin Invest 56:1108-1117, 1975
31. Brunzell JD, Schwartz RS, Eckel RH, Goldberg AP: Insulin and adipose tissue lipoprotein lipase in humans. Int J Obes 5:685-694, 1981
32. Homan R, Grossman JE, Pownall HJ: Differential effects of eicosapentaenoic acid and oleic acid on lipid synthesis and secretion by HepG2 cells. J Lipid Res 32:231-241, 1991
33. Xu X, Shang A, Jiang H, Ginsberg HN: Demonstration of biphasic effects of docosahexaenoic acid on apolipoprotein B secretion in HepG2 cells. Arterioscler Thromb Vasc Biol 17:3347-3355, 1997
34. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB: Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 24:147-155, 1983
35. Packard CJ, Shepherd J: Lipoprotein heterogeneity and apolipoprotein B metabolism. Arteriosder Thromb Vasc Biol 17:3542-3556, 1997
36. Magill P, Rao SN, Miller NE, Nicoll AM, Brunzell JD, St. Hilaire RJ, Lewis B: Relationships between the metabolism of high density and very low-density lipoproteins in man: studies of apolipoprotein kinetics and adipose tissue lipoprotein lipase activity. Eur J Clin Invest 12:113-120, 1982
37. Brinton EA, Eisenberg S, Breslow JL: Elevated high density lipoprotein cholesterol levels correlate with decreased apo A-I and apo A-II fractional catabolic rate in women. J Clin Invest 84:262-269, 1989
38. Desprès J-P, Ferland M, Moorjani S, Nadeau A, Tremblay A, Lupien PJ, Theriault G, Bouchard C: Role of hepalic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women. Arteriosclerosis 9:485-492, 1989
39. Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S: Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis 4:225-231, 1984
40. Capell WH, Zambon A, Austin MA, Brunzell JD, Hokanson JE: Compositional differences of low density lipoprotein particles in normal subjects with LDL subclass A and LDL subclass B. Arterioscler Thromb Vasc Biol 16:1040-1046, 1996
41. Houmard JA, Wheeler WS, McCammon MR, Wells JM, Truitt N, Hamad SF, Holbert D, Israel RG, Barakat HA: An evaluation of waist to hip ratio measurement methods in relation to lipid and carbohydrate metabolism in men. Int J Obes 15:181-188, 1991
42. Peeples LH, Carpenter JW, Israel RG, Barakal HA: Alterations in low-density lipoproteins in subjects with abdominal adiposity. Metabolism 38:1029-1036, 1989
43. Perusse L, Rice T, Despres J-P, Bergeron J, Province MA, Gagnon J, Lcon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C: Familial resemblance of plasma lipids, lipoproteins and postheparin lipoprotein and hepatic lipases in the Heritage Family Study. Arterioscler Thromb Vasc Biol 17:3263-3269, 1997
44. Austin MA, Edwards KL: Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependem diabetes. Curr Opin Lipidol 7:167-171, 1996
45. Lamarche B, Tchernol A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Desprès J-P: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 95:69-75, 1997
46. 2 cholesterol. Arteriosclerosis 5:273-282, 1985
47. Auwerx JH, Marzetta CA, Hokanson JE, Brunzell JD: Large buoyant LDE-like panicles in hepatic lipase deficiency. Arteriosclerosis 9:319-325, 1989
48. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD: Effect of hepatic lipase on LDL in normal men and those with coronary heart disease. Arterioscler Thromb 13:147-153, 1993
49. Watson TD, Caslake MJ, Freeman DJ, Griffin BA, Hinnie J, Packard CJ, Shepherd J: Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. Ancrioscler Thromb 14:902-910, 1994
50. 2 cholesterol. Arteriosler Thromb Vasc Biol 18:1723-1729, 1998
51. Kuusi T, Ehnholm C, Viikari J, Härkönen R, Vaniainen E, Paska P, Taskmen M-R: Postheparin plasma lipoprotein and hepatic lipase are determinants of hypo- and hyperalphalipoproteinemia. J Lipid Res 30:1117-1126, 1989
52. 2: relationship of the plasma level of this lipoprotcin species to its composition, to the magnitude of postprandial lipdemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 80:341-347, 1987
53. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM: Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein panicles. J Clin Invest 92:141-146, 1993
54. Brunzell JD, Nevin DN, Schwartz RS, Fujimoto WY: Low density lipoprotein subclass phenotype as a biochemical marker for visceral obesity and insulin resistance. In Molecular and Genetic Aspects of Obesity. Bray GA, Ryan DH, Eds. Baton Rouge, Louisiana State University Press. 1996, p. 355-363
55. Haffner SM, Mykkanen L, Robbins D, Valdez R, Miettinen H, Howard BV, Stern MP, Bowsher R: A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects. Diabetologia 38:1328-1336, 1995
56. Tchernof A, Lamarche B, Prudhomme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Desprès J-P: The dense LDL phenotype: association with plasma lipoprotcin levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19:629-637, 1996
57. Bergman RN: New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog Horm Res 52:359-385, 1997
58. Brunzell JD, Chait A: Diabetic dyslipidemia-pathology and treatment. In Ellenberg and Rifkin's Diabetes Mellitus. Pone D Jr, Sherwin J, Eds. Norwalk, CT, Appleton and Lange, 1996, p. 1077-1096
59. Bredie SJH, van Drongelen J, Kiemeney LA, Demacker PNM, Beaty TH, Stalenhoef AFH: Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 17:834-840, 1997
60. Ascaso JE, Merchante A, Real J, Lorente R, Martinez-Valls J, Carmena R: Influence of obesity on plasma lipoproteins, glycaemia and insulinaemia in patients with familial combined hyperlipidaemia. Int J Obes 21:360-366, 1997
61. Pihlajamäki J, Rissanen J, Heikkinen S, Karjalainen L, Laakso M: Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia. Aeterioscler Thromb Vasc Biol 17:1039-1044, 1997
62. Jarvik GP, Brunzell JD, Austin MA, Krauss RM, Motulsky AG, Wijsman E: Genetic predictors of FCHL in four large pedigrees: influence of apolipoprotein B level major locus predicted genotype and LDL subclass phenotype. Arterioscler Thromb Vasc Biol 14:1687-1694, 1994
63. Purnell JQ, Kahn SE, Schwartz RS, Brunzell JD: Evidence lor genetic control of elevated lipid and apo B levels, in addition to visceral obesity/insulin resistance in FCHL (Abstract). J Invest Med 45:105A, 1997
64. Guerra R, Wang J, Grundy SM, Cohen JC: A hepatic lipase (LIPC) allelc associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci USA 94:4532-4537, 1997
65. Murtomaki S, Tahvanianen E, Antikainen M, Tiret L, Nicaud V, Jansen H, Ehnholm C: Hepatic lipase gene polymorphism influence plasma HDE levels: results from Finnish EARS participants. Arterioscler Thromb Vasc Biol 17:1879-1884, 1997
66. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196-1204, 1991
67. Melish J, Le N, Ginsberg H, Steinberg D, Brown WY: Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins. Am J Physiol 239:E354-E362, 1980
68. Purnell JQ, Brunzell JD: The central role of dietary fat, not carbohydrate, in the insulin resistance syndrome. Curr Opin Lipidol 8:17-22, 1997
69. Zamhon A, Hokanson JE, Brown BG, Brunzell JD: Evidence lor a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase mediated changes in LDL density. Circulation. In press